Plasmid dna manufacturing market
Plasmid DNA Manufacturing Market, By Product Type (Viral Vectors, Plasmid DNA and Non-viral Vectors), By Grade (GMP Grade, R&D Grade and Clinical Grade), By Application (DNA Vaccines, Gene Therapy, Immunotherapy, RNA Vaccines and Others), By Manufacturing Type (Outsourcing and In-house Manufacturing), By Development Phase (Pre-Clinical Therapeutics, Clinical Therapeutics and Marketed Therapeutics), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
- Jan 2023
- CMI2593
- 266 Pages
- Excel & Pdf
- Biotechnology
Plasmids are small circular molecules of DNA found in bacteria and other microscopic organisms. Plasmids are physically separated from the chromosomal DNA and replicate independently. They usually have a small number of genes, especially those associated with antibiotic resistance, that are passed from one cell to another. Plasmid DNA can be used directly as therapeutic agents, such as gene therapy and vaccine antigen generation, or indirectly for a variety of research applications such as the use of plasmid DNA as a key starting material for transient transfection.
Global plasmid DNA manufacturing market is estimated to be valued at US$ 735.67 million in 2022 and is expected to exhibit a CAGR of 22.5% during the forecast period (2022-2030).
Figure 1.Global Plasmid DNA Manufacturing Market Share (%), by Grade, 2022
Global Plasmid DNA Manufacturing Market- Driver
The increasing demand for plasmid (pDNA) DNA and increasing research and development activities by key players in the market is expected to drive the market growth over the forecast period. For instance, in October 2022, Forge Biologics, a contract development and manufacturing organization, announced the addition of plasmid DNA manufacturing to its Columbus, Ohio facility. The plasmid DNA manufacturing services encompass three grades which includes research grade, for discovery, research and development, etc.
Figure 2. Global Plasmid DNA Manufacturing Market Share (%), by Region, 2022
The increasing Inorganic strategies such as collaboration by key players in the market to expand product portfolio is expected to drive the market growth over the forecast period. For instance, in September 2022, Lonza, a global manufacturing partner to the pharma, biotech, and nutrition industries, announced its collaboration with Touchlight, a biotechnology company pioneering enzymatic DNA production, to enable the genetic medicine revolution. This collaboration will further help Lonza to integrate an additional, differentiated source of DNA in its end-to-end offering to customers developing messenger RNA therapeutics and vaccines.
Global Plasmid DNA Manufacturing Market– Impact of Coronavirus (COVID-19) Pandemic
Coronavirus disease 2019 (COVID-19) is a highly contagious infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), according to World Health Organization (WHO) as of October 10, 2022, 44,614,437 people are affected worldwide.
The key players operating in the market are focusing on development of DNA vaccines for the treatment of Covid -19. For instance, in May 2020, AGC Biologics, a global contract development and manufacturing organization (CDMO) for biopharmaceuticals, partnered with Takara Bio, the biomedical business unit of Takara Shuzo Co., Ltd., to develop vaccine for COVID-19. As a result of this partnership, AGC Biologics is manufacturing the plasmid DNA intermediate vaccine for treatment of COVID-19 with Takara Bio.
Global Plasmid DNA Manufacturing Market: Key Developments
On October 10, 2022, Ray Therapeutics, a biotechnology company developing optogenetic gene therapies for patients with retinal degenerative conditions, and Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced further collaboration for their manufacturing partnership to include clinical stage plasmid DNA production to support Ray Therapeutics’ lead optogenetics gene therapy program, RTx-015, in clinical trials for patients with retinitis Pigmentosa. By adding clinical grade plasmid production to their existing suite of associated viral vector (AAV) manufacturing capabilities, Forge is easing the scope of production and accelerating the development of lead therapeutic.
On August 26, 2021, INOVIO, a biotechnology company announced that it had received regulatory authorization from Brazil's ANVISA (Agência Nacional de Vigilância Sanitária), the national health regulatory agency of Brazil, to initiate the global Phase 3 segment of its Phase 2/3 trial, INNOVATE (INOVIO INO-4800 Vaccine Trial for Efficacy), for INO-4800, its DNA vaccine candidate for COVID-19. INOVIO plans to conduct the global INNOVATE Phase 3 segment in multiple countries, including Brazil, with partner Advaccine Biopharmaceuticals Suzhou Co., Ltd. (Advaccine).
Plasmid DNA Manufacturing Market Report Coverage
Report Coverage | Details | ||
---|---|---|---|
Base Year: | 2021 | Market Size in 2022: | US$ 735.67 Mn |
Historical Data for: | 2017 to 2020 | Forecast Period: | 2022 to 2030 |
Forecast Period 2022 to 2030 CAGR: | 22.5% | 2030 Value Projection: | US$ 3,733.50 Mn |
Geographies covered: |
|
||
Segments covered: |
|
||
Companies covered: |
Cobra Biologics and Pharmaceutical Services (Charles River Laboratories), VGXI, Inc., Aldevron (Danaher), Kaneka Corporation, Nature Technology, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, LakePharma, Inc., MeiraGTx Limited, Eurofins Genomics, Vigene Biosciences, Luminous BioSciences (LBS), LLC, GenScript, GENEWIZ, Creative Biogene, Akron Biotech, Biomay, JAFRAL Ltd., WuXi Biologics, GeneImmune Biotechnology Corp., Lonza, Greenpak Biotech Ltd., Luina Bio (AcuraBio), Ajinomoto Bio-Pharma, Synbio Technologies, Genopis Inc., Altogen Biosystems, Puresyn, Inc., Cepham Life Sciences, Catalent, Inc., Biomiga, Waisman Biomanufacturing |
||
Growth Drivers: |
|
||
Restraints & Challenges: |
|
Global Plasmid DNA Manufacturing Market: Restraint
The high cost of gene therapies is adversely affecting the market growth. For instance, according to an article published by PubMed in May 2021, an upfront price of US$ 2.125 million, the one-time gene therapy onasemnogene abeparvovec for spinal muscular atrophy, a rare neuromuscular disorder that is usually fatal by 2 years of age if untreated, has been called the "most expensive drug ever”. Therefore, it is essential to lower the prices quoted by companies in order to increase the market reach.
Global Plasmid DNA Manufacturing Market: Key Players
Major players operating in the global plasmid DNA manufacturing market include Cobra Biologics and Pharmaceutical Services (Charles River Laboratories), VGXI, Inc., Aldevron (Danaher), Kaneka Corporation, Nature Technology, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, LakePharma, Inc., MeiraGTx Limited, Eurofins Genomics, Vigene Biosciences, Luminous BioSciences (LBS), LLC, GenScript, GENEWIZ, Creative Biogene, Akron Biotech, Biomay, JAFRAL Ltd., WuXi Biologics, GeneImmune Biotechnology Corp., Lonza, Greenpak Biotech Ltd., Luina Bio (AcuraBio), Ajinomoto Bio-Pharma, Synbio Technologies, Genopis Inc., Altogen Biosystems, Puresyn, Inc., Cepham Life Sciences, Catalent, Inc., Biomiga, Waisman Biomanufacturing
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By Grade
- Market Snapshot, By Application
- Market Snapshot, By Manufacturing Type
- Market Snapshot, By Development Phase
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Attractiveness Analysis
- Market Opportunities
- Product Launches
- Merger, Acquisition, Collaborations
- Regulatory Guideline and Compliances
- Key Developments
- PEST Analysis
- Technology Landscape
- PORTER’s Analysis
- Pricing Analysis (2021)
- Guidelines Specific for the Development of Plasmid DNA Vaccines
- Genomic Titer
- Market Dynamics
- Global Plasmid DNA Manufacturing Market– - Impact of Coronavirus (Covid-19) Pandemic
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
- Global Plasmid DNA Manufacturing Market, By Product Type, 2017 – 2030, (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Viral Vectors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Retroviral
- Adenoviral
- Lentiviral
- Adeno Associates
- Others
- Plasmid DNA
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- mRNA
- Others
- Non-viral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Lipid/Polymer
- Electroporation
- Nanoparticles
- Others
- Introduction
- Global Plasmid DNA Manufacturing Market, By Grade, 2017 – 2030, (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- GMP Grade
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- R&D Grade
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Clinical Grade
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Introduction
- Global Plasmid DNA Manufacturing Market, By Application, 2017 – 2030, (US$ Million
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segments Trends
- DNA Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- RNA Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Introduction
- Global Plasmid DNA Manufacturing Market, By Manufacturing Type, 2017 – 2030, (US$ Million
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segments Trends
- Outsourcing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- In-house Manufacturing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Introduction
- Global Plasmid DNA Manufacturing Market, By Development Phase, 2017 – 2030, (US$ Million
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segments Trends
- Pre-Clinical Therapeutics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Clinical Therapeutics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Marketed Therapeutics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Introduction
- Global Plasmid DNA Manufacturing Market, By Region, 2017 – 2030, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2030
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Grade, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Manufacturing Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Grade, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Manufacturing Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2017 - 2030, (US$ Million
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Grade, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Manufacturing Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2017 - 2030, (US$ Million
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Grade, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Manufacturing Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2017 - 2030, (US$ Million
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Grade, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Manufacturing Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2017 - 2030, (US$ Million
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Grade, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Manufacturing Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2017 - 2030, (US$ Million
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 – 2030, (US$ Million)
- North Africa
- Central Africa
- South Africa
- Introduction
- Competitive Landscape
- Cobra Biologics and Pharmaceutical Services (Charles River Laboratories).*
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- VGXI, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Aldevron (Danaher)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Kaneka Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Nature Technology
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- PlasmidFactory GmbH & Co. KG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Cell and Gene Therapy Catapult
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- LakePharma, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- MeiraGTx Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eurofins Genomics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Vigene Biosciences
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Luminous BioSciences (LBS), LLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- GenScript
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- GENEWIZ
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Creative Biogene
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Akron Biotech
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Biomay
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- JAFRAL Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- WuXi Biologics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- GeneImmune Biotechnology Corp.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Lonza
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Greenpak Biotech Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Luina Bio (AcuraBio)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Ajinomoto Bio-Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Synbio Technologies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Genopis Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Altogen Biosystems
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Puresyn, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Cepham Life Sciences
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Catalent, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Biomiga
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Waisman Biomanufacturing
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Cobra Biologics and Pharmaceutical Services (Charles River Laboratories).*
- Section
- Research Methodology
- About Us
*Browse 58 market data tables and 53 figures on “Plasmid DNA Manufacturing Market” - forecast to 2030
Detailed Segmentation:
- Global Plasmid DNA Manufacturing Market, By Product Type:
- Viral Vectors
- Retroviral
- Adenoviral
- Lentiviral
- Adeno Associates
- Others
- Plasmid DNA
- mRNA
- Others
- Non-viral
- Lipid/Polymer
- Electroporation
- Nanoparticles
- Others
- Viral Vectors
- Global Plasmid DNA Manufacturing Market, By Grade:
- GMP Grade
- R&D Grade
- Clinical Grade
- Global Plasmid DNA Manufacturing Market By Application:
- DNA Vaccines
- Gene Therapy
- Immunotherapy
- RNA Vaccines
- Others
- Global Plasmid DNA Manufacturing Market By Manufacturing Type:
- Outsourcing
- In-house Manufacturing
- Global Plasmid DNA Manufacturing Market By Development Phase:
- Pre-Clinical Therapeutics
- Clinical Therapeutics
- Marketed Therapeutics
- Global Plasmid DNA Manufacturing Market, By Region:
- North America
- By Product Type:
- Viral Vectors
- Retroviral
- Adenoviral
- Lentiviral
- Adeno Associates
- Others
- Plasmid DNA
- mRNA
- Others
- Non-viral
- Lipid/Polymer
- Electroporation
- Nanoparticles
- Others
- Viral Vectors
- By Grade:
- GMP Grade
- R&D Grade
- Clinical Grade
- By Application:
- DNA Vaccines
- Gene Therapy
- Immunotherapy
- RNA Vaccines
- Others
- By Manufacturing Type:
- Outsourcing
- In-house Manufacturing
- By Development Phase:
- Pre-Clinical Therapeutics
- Clinical Therapeutics
- Marketed Therapeutics
- By Country:
- U.S.
- Canada
- By Product Type:
- Latin America
- By Product Type:
- Viral Vectors
- Retroviral
- Adenoviral
- Lentiviral
- Adeno Associates
- Others
- Plasmid DNA
- mRNA
- Others
- Non-viral
- Lipid/Polymer
- Electroporation
- Nanoparticles
- Others
- Viral Vectors
- By Grade:
- GMP Grade
- R&D Grade
- Clinical Grade
- By Application:
- DNA Vaccines
- Gene Therapy
- Immunotherapy
- RNA Vaccines
- Others
- By Manufacturing Type:
- Outsourcing
- In-house Manufacturing
- By Development Phase:
- Pre-Clinical Therapeutics
- Clinical Therapeutics
- Marketed Therapeutics
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Product Type:
- Europe
- By Product Type:
- Viral Vectors
- Retroviral
- Adenoviral
- Lentiviral
- Adeno Associates
- Others
- Plasmid DNA
- mRNA
- Others
- Non-viral
- Lipid/Polymer
- Electroporation
- Nanoparticles
- Others
- Viral Vectors
- By Grade:
- GMP Grade
- R&D Grade
- Clinical Grade
- By Application:
- DNA Vaccines
- Gene Therapy
- Immunotherapy
- RNA Vaccines
- Others
- By Manufacturing Type:
- Outsourcing
- In-house Manufacturing
- By Development Phase:
- Pre-Clinical Therapeutics
- Clinical Therapeutics
- Marketed Therapeutics
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Product Type:
- Asia Pacific
- By Product Type:
- Viral Vectors
- Retroviral
- Adenoviral
- Lentiviral
- Adeno Associates
- Others
- Plasmid DNA
- mRNA
- Others
- Non-viral
- Lipid/Polymer
- Electroporation
- Nanoparticles
- Others
- Viral Vectors
- By Grade:
- GMP Grade
- R&D Grade
- Clinical Grade
- By Application:
- DNA Vaccines
- Gene Therapy
- Immunotherapy
- RNA Vaccines
- Others
- By Manufacturing Type:
- Outsourcing
- In-house Manufacturing
- By Development Phase:
- Pre-Clinical Therapeutics
- Clinical Therapeutics
- Marketed Therapeutics
- By Country:
- India
- China
- Japan
- Australia
- ASEAN
- South Korea
- Rest of Middle East
- By Product Type:
- Middle East
- By Product Type:
- Viral Vectors
- Retroviral
- Adenoviral
- Lentiviral
- Adeno Associates
- Others
- Plasmid DNA
- mRNA
- Others
- Non-viral
- Lipid/Polymer
- Electroporation
- Nanoparticles
- Others
- Viral Vectors
- By Grade:
- GMP Grade
- R&D Grade
- Clinical Grade
- By Application:
- DNA Vaccines
- Gene Therapy
- Immunotherapy
- RNA Vaccines
- Others
- By Manufacturing Type:
- Outsourcing
- In-house Manufacturing
- By Development Phase:
- Pre-Clinical Therapeutics
- Clinical Therapeutics
- Marketed Therapeutics
- By Country:
- GCC
- Isreal
- Japan
- By Product Type:
- Africa
- By Product Type:
- Viral Vectors
- Retroviral
- Adenoviral
- Lentiviral
- Adeno Associates
- Others
- Plasmid DNA
- mRNA
- Others
- Non-viral
- Lipid/Polymer
- Electroporation
- Nanoparticles
- Others
- Viral Vectors
- By Grade:
- GMP Grade
- R&D Grade
- Clinical Grade
- By Application:
- DNA Vaccines
- Gene Therapy
- Immunotherapy
- RNA Vaccines
- Others
- By Manufacturing Type:
- Outsourcing
- In-house Manufacturing
- By Development Phase:
- Pre-Clinical Therapeutics
- Clinical Therapeutics
- Marketed Therapeutics
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Product Type:
- North America